- Home
- WRN vs AMRN Comparison
WRN vs AMRN Comparison
Compare WRN & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WRN | AMRN |
|---|---|---|
| Founded | 2006 | 1989 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 609.2M | 287.9M |
| IPO Year | 2006 | 1998 |
Fundamental Metrics
Financial Performance| Metric | WRN | AMRN |
|---|---|---|
| Price | $2.39 | $13.42 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 3 | 1 |
| Target Price | $4.58 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 1.0M | 79.0K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $1.78 | $12.96 |
| 52 Week High | $4.26 | $20.90 |
Technical Indicators
Market Signals| Indicator | WRN | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 48.35 | 38.27 |
| Support Level | $2.28 | N/A |
| Resistance Level | $2.61 | $14.50 |
| Average True Range (ATR) | 0.11 | 0.39 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 42.86 | 19.09 |
Price Performance
Historical ComparisonAbout WRN Western Copper and Gold Corporation
Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project). The Casino can deliver the critical minerals necessary for the energy transition while serving as an engine for long-term economic growth and prosperity in the North.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.